Long-term Clinical Observation of Topiramate in the Treatment of Epilepsy
伍文清(Wen-Qing Wu)；潘映輻(Ying-Fu Pan)
癲癇 ； 妥泰 ； 長期治療 ； Epilepsy ； Topiramate (TPM) ； Long-term therapy
|Volume or Term/Year and Month of Publication||
24卷4期（2002 / 08 / 10）
247 - 250
目的 觀察長期應用妥泰治療癲癇的臨床療效、不良反應。方法 118例癲癇患者分為加用妥泰組和妥泰單藥治療組，觀察時間為6～27個月，平均12.7個月。結果 妥泰對各型癲癇治療的總有效率為82.1%，其中全身強直-陣攣性發作(GTCS)總有效率為83.3%，簡單部分性發作(SPS)總有效率為87.5%，複雜部分性發作(CPS)總有效率為72.0%，Lennox-Gastaut綜合徵(L-GS)總有效率為100%，其他［包括強直性發作(TS)、肌陣攣性發作(MCS)］總有效率為55.7%；服藥時間1年以上者總有效率為81.1%，控制率為52.0%；單藥治療的總有效率及控制率分別為80.6%、63.9%，輔助治療的總有效率及控制率分別為82.9%、41.4%；輕、中度病人的總有效率及控制率分別為84.0%、66.0%，重度病人的總有效率及控制率分別為80.3%、33.9%。結論 妥泰長期單藥及輔助治療各型癲癇效果明顯、穩定，無耐藥性，不良反應小；妥泰劑量應個體化。
Objective To evaluate the long-term efficacy and side effects of topiramate (TPM) in the treatment of the patients with epilepsy. Methods A total 118 patients with seizures were devided into two groups, one was treated with TPM as add-on therapy; another was TPM monotherapy. The mean duration of TPM was 12.7 months (6～27 months). Seizure reductions were calculated from seizure counts during the last 3 months of TPM therapy compared with baseline. Results Overall effective rate was 82.1%. (≥50% seizure reduction), GTCS was in 83.3% , SPS was in 87.5%, CPS was in 72%, L-GS was in 100% and others (TS、MCs) were in 85.7% .Among the patients treated 12 months, effective rate was 81.1% (50% seizure reduction); control rate was 52% (seizure free). Among patients treated with TPM as monotherapy, effective rate and control rate were 80.6% and 63.9% respectively; in the add-on treatment they were 82.9% and 41.4% respectively. Patients with refractory epilepsy effective rate and control rate were 80.3% and 33.9% respectively; and in non-refractory group, they were 84% and 66 % respectively. Conclusions TPM is a well-tolerated and useful agent for long-term seizure cortrol no whether as adjunctive therapy and (or) as monotherapy.